225 related articles for article (PubMed ID: 28138033)
1. Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform.
Morry J; Ngamcherdtrakul W; Gu S; Reda M; Castro DJ; Sangvanich T; Gray JW; Yantasee W
Mol Cancer Ther; 2017 Apr; 16(4):763-772. PubMed ID: 28138033
[TBL] [Abstract][Full Text] [Related]
2. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
Hu K; Law JH; Fotovati A; Dunn SE
Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
[TBL] [Abstract][Full Text] [Related]
3. PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer.
Reda M; Ngamcherdtrakul W; Gu S; Bejan DS; Siriwon N; Gray JW; Yantasee W
Cancer Lett; 2019 Dec; 467():9-18. PubMed ID: 31563561
[TBL] [Abstract][Full Text] [Related]
4. Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells.
Ha GH; Kim DY; Breuer EK; Kim CK
Anticancer Res; 2018 Mar; 38(3):1303-1310. PubMed ID: 29491053
[TBL] [Abstract][Full Text] [Related]
5. pH-responsive hybrid nanoparticle with enhanced dissociation characteristic for siRNA delivery.
Shi M; Zhao X; Zhang J; Pan S; Yang C; Wei Y; Hu H; Qiao M; Chen D; Zhao X
Int J Nanomedicine; 2018; 13():6885-6902. PubMed ID: 30498349
[TBL] [Abstract][Full Text] [Related]
6.
Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
[TBL] [Abstract][Full Text] [Related]
7. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
Bhola NE; Jansen VM; Bafna S; Giltnane JM; Balko JM; Estrada MV; Meszoely I; Mayer I; Abramson V; Ye F; Sanders M; Dugger TC; Allen EV; Arteaga CL
Cancer Res; 2015 Jan; 75(2):405-14. PubMed ID: 25480943
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of PLK1 inhibition in triple-negative breast cancer.
Ueda A; Oikawa K; Fujita K; Ishikawa A; Sato E; Ishikawa T; Kuroda M; Kanekura K
Lab Invest; 2019 Sep; 99(9):1275-1286. PubMed ID: 30996295
[TBL] [Abstract][Full Text] [Related]
9. Glucose-linked sub-50-nm unimer polyion complex-assembled gold nanoparticles for targeted siRNA delivery to glucose transporter 1-overexpressing breast cancer stem-like cells.
Yi Y; Kim HJ; Zheng M; Mi P; Naito M; Kim BS; Min HS; Hayashi K; Perche F; Toh K; Liu X; Mochida Y; Kinoh H; Cabral H; Miyata K; Kataoka K
J Control Release; 2019 Feb; 295():268-277. PubMed ID: 30639386
[TBL] [Abstract][Full Text] [Related]
10. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
[TBL] [Abstract][Full Text] [Related]
11. Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
Jeong SB; Im JH; Yoon JH; Bui QT; Lim SC; Song JM; Shim Y; Yun J; Hong J; Kang KW
Mol Cancer Ther; 2018 Apr; 17(4):825-837. PubMed ID: 29437878
[TBL] [Abstract][Full Text] [Related]
12. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
Gerster K; Shi W; Ng B; Yue S; Ito E; Waldron J; Gilbert R; Liu FF
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):253-60. PubMed ID: 20394857
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
[TBL] [Abstract][Full Text] [Related]
14. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells.
Han DP; Zhu QL; Cui JT; Wang PX; Qu S; Cao QF; Zong YP; Feng B; Zheng MH; Lu AG
Med Sci Monit; 2012 Jun; 18(6):BR237-46. PubMed ID: 22648245
[TBL] [Abstract][Full Text] [Related]
16. CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression.
Kong Y; Yang L; Wei W; Lyu N; Zou Y; Gao G; Ou X; Xie X; Tang H
Epigenomics; 2019 Aug; 11(10):1163-1176. PubMed ID: 31337246
[No Abstract] [Full Text] [Related]
17. Folate-Mediated Targeted Delivery of siPLK1 by Leucine-Bearing Polyethylenimine.
Hou L; Song Z; Xu Z; Wu Y; Shi W
Int J Nanomedicine; 2020; 15():1397-1408. PubMed ID: 32184594
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis.
Yao YD; Sun TM; Huang SY; Dou S; Lin L; Chen JN; Ruan JB; Mao CQ; Yu FY; Zeng MS; Zang JY; Liu Q; Su FX; Zhang P; Lieberman J; Wang J; Song E
Sci Transl Med; 2012 Apr; 4(130):130ra48. PubMed ID: 22517885
[TBL] [Abstract][Full Text] [Related]
19. Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells.
Francescangeli F; Patrizii M; Signore M; Federici G; Di Franco S; Pagliuca A; Baiocchi M; Biffoni M; Ricci Vitiani L; Todaro M; De Maria R; Zeuner A
Stem Cells; 2012 Sep; 30(9):1819-30. PubMed ID: 22753241
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]